Please login to the form below

Not currently logged in
Email:
Password:

MSD

This page shows the latest MSD news and features for those working in and with pharma, biotech and healthcare.

Keytruda doubles five-year survival rate in NSCLC

Keytruda doubles five-year survival rate in NSCLC

Merck reveals long-term efficacy data for blockbuster immunotherapy. Merck &Co/MSD’s Keytruda (pembrolizumab) doubled the five-year survival rate for patients with metastatic non-small cell lung cancer (NSCLC)

Latest news

More from news
Approximately 63 fully matching, plus 360 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 4 fully matching, plus 33 partially matching documents found.

Latest appointments

More from appointments
Approximately 5 fully matching, plus 48 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 18 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
11 London

11 London is a strategic and creative agency working in the fields of health and humanity – complex areas, but...

Latest intelligence

Has the pandemic opened up a future of accelerated diagnosis and better care for rare disease patients?
The challenge with rare disease is in the name – it's rare, so awareness is limited and diagnosis hindered. Could a more virtual existence change this? A Medical Affairs viewpoint...
The other side of … blood cancer
To stay motivated for the fight, some patients need to feel like active players in the treatment journey, not passengers to every decision....
COVID clinical trial
COVID-19 – a catalyst for technology adoption in clinical trials
As the COVID-19 crisis disrupts clinical trials around the globe, it is also proving to be a catalyst that may transform its approach to trials for good...

Infographics